Nurix Therapeutics, Inc.
NRIX
$15.96
-$0.32-1.97%
NASDAQ
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Net Income | -41.69% | -36.62% | -38.32% | -25.65% | -43.99% |
| Total Depreciation and Amortization | 16.50% | 20.68% | 18.96% | 19.34% | 18.56% |
| Total Amortization of Deferred Charges | -53.85% | -53.85% | -7.14% | -7.14% | -7.14% |
| Total Other Non-Cash Items | 35.63% | 20.79% | 6.21% | -10.29% | -17.60% |
| Change in Net Operating Assets | 38.48% | -71.71% | -174.05% | -274.84% | -177.88% |
| Cash from Operations | -35.77% | -44.55% | -137.16% | -123.91% | -156.09% |
| Capital Expenditure | -17.10% | -51.00% | -12.54% | -7.57% | -9.61% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 103.90% | 165.15% | 114.54% | 29.47% | -366.47% |
| Cash from Investing | 99.44% | 157.37% | 105.10% | 25.28% | -405.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -47.04% | -50.86% | -28.76% | 2.77% | 14,350.33% |
| Repurchase of Common Stock | -- | -- | 100.00% | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -47.04% | -50.86% | -28.76% | 2.77% | 14,349.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -117.83% | 147.48% | -136.20% | -156.25% | 60.71% |